as 07-26-2024 4:00pm EST
Cencora is one of three domestic leading pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health constitute over 90% of the us pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.
Upcoming Earnings Alert:
Get ready for potential market movements as Cencora Inc. COR prepares to release earnings report on 31 Jul 2024.
Founded: | 2001 | Country: | United States |
Employees: | N/A | City: | CONSHOHOCKEN |
Market Cap: | 43.7B | IPO Year: | N/A |
Target Price: | $253.17 | AVG Volume (30 days): | 1.1M |
Analyst Decision: | Buy | Number of Analysts: | 6 |
Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
EPS: | 9.15 | EPS Growth: | 17.46 |
52 Week Low/High: | $171.65 - $246.75 | Next Earning Date: | 07-31-2024 |
Revenue: | $276,536,514,000 | Revenue Growth: | 11.71% |
Revenue Growth (this year): | 11.82% | Revenue Growth (next year): | 6.82% |
Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
---|---|---|---|---|---|---|---|---|---|
COLLIS STEVEN H | COR | Chairman, President & CEO | Jul 16 '24 | Sell | $222.12 | 10,755 | $2,388,900.60 | 285,088 | SEC Form 4 |
COLLIS STEVEN H | COR | Chairman, President & CEO | Jun 18 '24 | Sell | $235.76 | 10,754 | $2,535,363.04 | 285,088 | SEC Form 4 |
Clark Gina | COR | Executive Vice President | May 31 '24 | Sell | $223.86 | 1,874 | $419,506.14 | 13,284 | SEC Form 4 |
DURCAN DERMOT MARK | COR | Director | May 24 '24 | Buy | $218.58 | 500 | $109,290.00 | 21,876 | SEC Form 4 |
Walgreens Boots Alliance, Inc. | COR | 10% Owner | May 22 '24 | Sell | $215.12 | 1,859,390 | $400,000,158.12 | 24,418,171 | SEC Form 4 |
COLLIS STEVEN H | COR | Chairman, President & CEO | May 21 '24 | Sell | $221.30 | 10,755 | $2,380,081.50 | 285,088 | SEC Form 4 |
COLLIS STEVEN H | COR | Chairman, President & CEO | Apr 16 '24 | Sell | $237.48 | 10,754 | $2,553,859.92 | 285,088 | SEC Form 4 |
Mauch Robert P. | COR | Executive Vice President & COO | Apr 15 '24 | Sell | $235.09 | 57,564 | $13,532,720.76 | 24,412 | SEC Form 4 |
COLLIS STEVEN H | COR | Chairman, President & CEO | Mar 19 '24 | Sell | $240.21 | 10,755 | $2,583,458.55 | 285,088 | SEC Form 4 |
Clark Gina | COR | Executive Vice President | Mar 18 '24 | Sell | $238.12 | 9,644 | $2,296,429.28 | 15,158 | SEC Form 4 |
Clark Gina | COR | Executive Vice President | Mar 18 '24 | Sell | $216.07 | 27,093 | $5,853,984.51 | 15,158 | SEC Form 4 |
Clark Gina | COR | Executive Vice President | Feb 13 '24 | Sell | $230.48 | 1,100 | $253,528.00 | 24,802 | SEC Form 4 |
COLLIS STEVEN H | COR | Chairman, President & CEO | Dec 13 '23 | Sell | $203.18 | 42,885 | $8,713,374.30 | 288,688 | SEC Form 4 |
COLLIS STEVEN H | COR | Chairman, President & CEO | Dec 12 '23 | Sell | $202.15 | 25,000 | $5,053,750.00 | 331,573 | SEC Form 4 |
Krikorian Lazarus | COR | SVP & Chief Accounting Officer | Dec 1 '23 | Sell | $203.60 | 2,000 | $407,204.00 | 19,876 | SEC Form 4 |
COLLIS STEVEN H | COR | Chairman, President & CEO | Nov 14 '23 | Sell | $197.63 | 25,000 | $4,940,750.00 | 331,573 | SEC Form 4 |
COR Breaking Stock News: Dive into COR Ticker-Specific Updates for Smart Investing
Simply Wall St.
14 hours ago
Zacks
2 days ago
Zacks
15 days ago
Simply Wall St.
16 days ago
GlobeNewswire
19 days ago
Business Wire
21 days ago
Argus Research
a month ago
Argus Research
a month ago
The information presented on this page, "COR Cencora Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.